Skip to content
etf.net

Launched · SEC filings

iShares Genomics Immunology and Healthcare ETF

IDNANYSE ArcaiSharesB

$41.70−1.06 (−2.48%)

At close: Nov 2, 2026, 4:00 PM ET

B55/ 100

Rank 8 of 17 in Biotech & Genomics

B55/100Rank 8 of 17inBiotech & Genomics
Intraday session: down, 79 prints from 42.76 to 41.70. Range 41.62 to 42.84. Use the arrow keys to read each point.42.0042.2542.5010 AM12 PM2 PM4 PM
Expense ratio
0.47%
Fund size
$335M
1Y total return
+70.3%
Yield · Last 12 months
0.66%
Holdings
61
Avg volume · 30D
121K sh
52W range
low $24.29high $43.79
Launched
Filings
SEC EDGAR

The ETF.net IDNA Grade

Based on 5 of 6 pillars

B

Score 55 out of 100

Category
Biotech & Genomics⁠
Rank
8 of 17
Six-pillar profile for IDNA. Scores out of 100: Cost 56, Risk 67, Mission not scored, Tradability 50, Holdings 39, Durability 62. Strongest: Risk (67). Weakest: Holdings (39). Based on 5 of 6 pillars.

Score 55 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    B56 out of 100
    Rank 7 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    B67 out of 100
    Rank 7 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    C50 out of 100
    Rank 7 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    D39 out of 100
    Rank 14 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    B62 out of 100
    Rank 7 of 17

Our read on IDNA

ETF.net Research

In short

BMost biotech ETFs hand you the US biotech index. IDNA goes narrower and wider at once: about 50 companies from developed and emerging markets, picked around genomics, immunology and bioengineering.

Stated mandate

The Fund seeks to track an index of developed- and emerging-market companies positioned to benefit from long-term growth and innovation in genomics, immunology, and bioengineering.

Why people hold it

  • The mandate is specific: an index of developed- and emerging-market companies tied to genomics, immunology and bioengineering, not a catch-all biotech basket.ishares.com
  • 0.47% a year, a shade under the typical fund in its genomics-and-biotech peer group.
  • About 50 holdings, so individual genomics and immunology names carry real weight instead of getting diluted inside a broad healthcare index.
  • Running since 2019 under the iShares roof, and it stands in the upper half of its biotech and genomics peer group.

Worth knowing

  • Concentration cuts both ways: about 50 stocks in one theme, so single-company clinical news lands harder here than in a broad healthcare fund.
  • Smaller and less actively traded than the category's giants, so limit orders earn their keep. Emerging-market holdings add currency and local-market risk.
  • Broad biotech index funds charge less, IBBQ at 0.19% and IBB at 0.44%; the extra basis points here buy the global genomics-and-immunology tilt.

IDNA Performance

Launched Jun 11, 2019

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.
IDNA$17,033
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. IDNA $17,033. SPY $11,199. Use the arrow keys to read each point.$10,000$12,500$15,000$17,500Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for IDNA. Periods over one year show the average yearly return.
PeriodIDNA
Year to date+64.0%
1 month+1.0%
3 months+32.3%
1 year+70.3%
3 yearsper year+34.7%
5 yearsper year−2.0%
10 yearsFund is under 10 years oldper yearNo data

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for IDNA
YearReturn barIDNA
2026 YTD+64.0%
2025+17.3%
2024−0.7%
2023−7.6%
2022−42.3%
2021−4.0%
2020+54.3%

IDNA in the news

IDNA Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
0.66%Last 12 months
Payout per share
$0.28Last 12 months
Last payment
$0.13 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Twice a year

Distribution history

2019–2026

One bar per payment. 13 payments from 2019 to 2026 YTD. Dec 16, 2019 $0.24; Jun 15, 2020 $0.08; Dec 14, 2020 $0.04; Jun 10, 2021 $0.05; Dec 13, 2021 $0.26; Jun 9, 2022 $0.14; Jun 7, 2023 $0.07; Dec 20, 2023 $0.17; Jun 11, 2024 $0.11; Dec 17, 2024 $0.11; Jun 16, 2025 $0.15; Dec 16, 2025 $0.16; Jun 15, 2026 $0.13. Use the arrow keys to read each point.20192020202120222023202420252026YTD
Ex-datePay dateAmount per share
Jun 15, 2026Jun 18, 2026$0.13
Dec 16, 2025Dec 19, 2025$0.16
Jun 16, 2025Jun 20, 2025$0.15
Dec 17, 2024Dec 20, 2024$0.11
Jun 11, 2024Jun 17, 2024$0.11
Dec 20, 2023Dec 27, 2023$0.17
Jun 7, 2023Jun 13, 2023$0.07
Jun 9, 2022Jun 15, 2022$0.14
Dec 13, 2021Dec 17, 2021$0.26
Jun 10, 2021Jun 16, 2021$0.05
Dec 14, 2020Dec 18, 2020$0.04
Jun 15, 2020Jun 19, 2020$0.08

See all 13 payments⁠

$10,000 in IDNA 5 years ago paid $263 in dividends.⁠

IDNA Risk

Risk pillarB67 out of 100Rank 7 of 17 in Biotech & Genomics
How much the fund’s monthly returns vary, scaled to a year.
23.6%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
1.20
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−65.7%
Trough Oct 2023
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
1.11
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

IDNA Cost

Compare IDNA and IBBQ

Overpaying vs IBBQ, cheapest in Biotech & Genomics

$5,466

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • IDNA 0.47%

    $9,418

  • IBBQ 0.19% Cheapest

    $3,952

$10,000
30 years

Cost over time

  • IDNA 0.47%
  • IBBQ 0.19%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2K$4K$6K$8K$10K051015202530IDNA $9,418IBBQ $3,952

Year by year

YearIDNAIBBQOverpaying
10$847$347$500
20$3,261$1,351$1,910
30$9,418$3,952$5,466

Other funds in Biotech & Genomics

See others